Terazosin Therapy For Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Randomized, Placebo Controlled Trial

Abstract

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Feb 2003Terazosin Therapy For Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Randomized, Placebo Controlled Trial PHAIK YEONG CHEAH, MEN LONG LIONG, KAH HAY YUEN, CHU LEONG TEH, TIMOTHY KHOR, JIN RONG YANG, HIN WAI YAP, and JOHN N. KRIEGER PHAIK YEONG CHEAHPHAIK YEONG CHEAH , MEN LONG LIONGMEN LONG LIONG , KAH HAY YUENKAH HAY YUEN , CHU LEONG TEHCHU LEONG TEH , TIMOTHY KHORTIMOTHY KHOR , JIN RONG YANGJIN RONG YANG , HIN WAI YAPHIN WAI YAP , and JOHN N. KRIEGERJOHN N. KRIEGER View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)63960-2AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We evaluate terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome. Materials and Methods: The study included 100, 20 to-50-year-old subjects who met the consensus criteria for chronic prostatitis/chronic pelvic pain syndrome and had not received previous α-blockers. Subjects were randomized to receive terazosin with dose escalation from 1 to 5 mg. daily or placebo for 14 weeks. The primary criterion for response was scoring 2 or less (“delighted-to-mostly satisfied”) on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) quality of life item. The secondary criterion for response was greater than 50% reduction in NIH-CPSI pain score at 14 weeks. Other outcomes included total and NIH-CPSI domain scores, International Prostate Symptom Score, peak urinary flow rate, post-void residual urine and adverse effects. Results: Using the primary criterion 24 of 43 evaluable subjects (56%) responded in the terazosin group compared to 14 of 43 (36%) in the placebo group (p = 0.03). Using the secondary criterion 26 of 43 subjects (60%) responded in the terazosin group compared to 16 of 43 (37%) in the placebo group (p = 0.03). The terazosin group had greater reductions (p <0.05) in NIH-CPSI total score, individual domain scores and International Prostate Symptom Score than the placebo group. There was no difference in peak urinary flow rate or post-void residual. In the terazosin group 18 patients (42%) had side effects compared to 9 (21%) in the placebo group (p = 0.04). Conclusions: Terazosin proved superior to placebo for patients with chronic prostatitis/chronic pelvic pain syndrome who had not received α-blockers previously. References 1 : Prevalence of prostatitis-like symptoms in a population-based study using the National Institutes of Health Chronic Prostatitis Symptom Index. J Urol2001; 165: 842. Abstract, Google Scholar 2 : Chronic prostatitis: symptom survey with follow-up clinical evaluation. J Urol2002; 167: 27. abstract 109. Google Scholar 3 : Sickness impact of chronic nonbacterial prostatitis and its correlates. J Urol1996; 155: 965. Link, Google Scholar 4 : What is the economic impact of chronic prostatitis?. J Urol2001; 165: 25. abstract 106. Google Scholar 5 : Research guidelines for chronic prostatitis: consensus report from the First National Institutes of Health Prostatitis Collaborative Network. Urology1999; 54: 229. Google Scholar 6 : Prostatodynia or painful male urethral syndrome?. Urology1990; 36: 146. Google Scholar 7 : Prostatodynia-physiological characteristics and rational management with muscle relaxants. Br J Urol1981; 53: 621. Google Scholar 8 : Use of terazosin in prostatodynia and validation of a symptom score questionnaire. Urology1994; 43: 460. Google Scholar 9 : Research in ‘prostatitis syndromes’: the use of Alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities. Eur Urol1992; 22: 222. Google Scholar 10 : Terazosin and tamsulosin in non bacterial prostatitis: a randomized placebo-controlled study. Arch Ital Urol Androl1999; 71: 283. Google Scholar 11 : NIH consensus definition and classification of prostatitis. JAMA1999; 282: 236. Crossref, Medline, Google Scholar 12 : The National Institutes of Health Chronic Prostatitis Symptom Index: development and validation of a new outcome measure. J Urol1999; 162: 369. Link, Google Scholar 13 : Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol1968; 5: 492. Google Scholar 14 : The American Urological Association symptom index for benign prostatic hyperplasia. J Urol1992; 148: 1549. Link, Google Scholar 15 : An improved approximate formula for calculating sample sizes for comparing binomial distributions. Biometrics1978; 34: 483. Google Scholar 16 : Split-plot design—factorial design with block treatment confounding. In: Experimental Design: Procedures for the Behavioral Sciences. California: Brooks/Cole Publishing Co.1968: 245. Google Scholar 17 : Chronic pelvic pains represent the most prominent urogenital symptom for “chronic prostatitis.”. Urology1996; 48: 715. Google Scholar 18 : Few patients with “chronic prostatitis” have significant bladder outlet obstruction. Urology1998; 52: 417. Google Scholar 19 : α1-Adrenergic receptor subtypes in human detrusor. J Urol1998; 160: 937. Link, Google Scholar 20 : Micturition in conscious rats with and without bladder outlet obstruction: role of spinal alpha 1-adrenoceptors. Br J Pharmacol1996; 117: 962. Crossref, Medline, Google Scholar From the School of Pharmaceutical Sciences, University of Science Malaysia, Department of Urology, Lam Wah Ee Hospital, Department of Urology, Penang Adventist Hospital, Department of Urology, Gleneagles Medical Center, Department of Urology, Penang Hospital, Department of Urology, Island Hospital, Penang, Malaysia, and the Department of Urological Surgery, University of Washington School of Medicine, Seattle, Washington© 2003 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byNickel J, O'Leary M, Lepor H, Caramelli K, Thomas H, Hill L and Hoel G (2011) Silodosin for Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Results of a Phase II Multicenter, Double-Blind, Placebo Controlled StudyJournal of Urology, VOL. 186, NO. 1, (125-131), Online publication date: 1-Jul-2011.Lee S, Cheah P, Liong M, Yuen K, Schaeffer A, Propert K and Krieger J (2018) Demographic and Clinical Characteristics of Chronic Prostatitis: Prospective Comparison of the University of Sciences Malaysia Cohort With the United States National Institutes of Health CohortJournal of Urology, VOL. 177, NO. 1, (153-158), Online publication date: 1-Jan-2007.Mishra V, Browne J and Emberton M (2018) Role of α-Blockers in Type III Prostatitis: A Systematic Review of the LiteratureJournal of Urology, VOL. 177, NO. 1, (25-30), Online publication date: 1-Jan-2007.NICKEL J, NARAYAN P, McKAY J and DOYLE C (2018) TREATMENT OF CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME WITH TAMSULOSIN: A RANDOMIZED DOUBLE BLIND TRIALJournal of Urology, VOL. 171, NO. 4, (1594-1597), Online publication date: 1-Apr-2004. Volume 169Issue 2February 2003Page: 592-596 Advertisement Copyright & Permissions© 2003 by American Urological Association, Inc.Keywordsprostatitisdrug therapychronic diseasepelvic painprostateMetrics Author Information PHAIK YEONG CHEAH Financial interest and/or other relationship with Abbott Laboratories. More articles by this author MEN LONG LIONG More articles by this author KAH HAY YUEN More articles by this author CHU LEONG TEH More articles by this author TIMOTHY KHOR More articles by this author JIN RONG YANG More articles by this author HIN WAI YAP More articles by this author JOHN N. KRIEGER Requests for reprints: Department of Urological Surgery, University of Washington School of Medicine, VA Puget Sound Health Care System, 1660 S. Columbian Way, Seattle, Washington 98108. More articles by this author Expand All Advertisement PDF downloadLoading ...